Literature DB >> 23652737

Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis: a cost-effectiveness analysis.

James Irlam1, Bongani M Mayosi, Mark Engel, Thomas A Gaziano.   

Abstract

BACKGROUND: Acute rheumatic fever and subsequent rheumatic heart disease remain significant in developing countries. We describe a cost-effective analysis of 7 strategies for the primary prevention of acute rheumatic fever and rheumatic heart disease in children presenting with pharyngitis in urban primary care clinics in South Africa. METHODS AND
RESULTS: We used a Markov model to assess the cost-effectiveness of treatment with intramuscular penicillin using each of the following strategies: (1) empirical (treat all); (2) positive throat culture (culture all); (3) clinical decision rule (CDR) score ≥2 (CDR 2+); (4) CDR score ≥3 (CDR 3+); (5) treating those with a CDR score ≥2 plus those with CDR score <2 and positive cultures (CDR 2+, culture CDR negatives); (6) treating those with a CDR score ≥3 plus those with CDR score <3 and positive cultures (CDR 3+, culture CDR negatives); and (7) treat none. The strategies ranked in order from lowest cost were treat all ($11.19 per child), CDR 2+ ($11.20); the CDR 3+ ($13.00); CDR 2+, culture CDR negatives ($16.42); CDR 3+, culture CDR negatives ($23.89); and culture all ($27.21). The CDR 2+ is the preferred strategy at less than $150/quality-adjusted life year compared with the treat all strategy. A strategy of culturing all children compared with the CDR 2+ strategy costs more than $125 000/quality-adjusted life year gained.
CONCLUSIONS: Treating all children presenting with pharyngitis in urban primary care clinics in South Africa with intramuscular penicillin is the least costly. A strategy of using a clinical decision rule without culturing is overall the preferred strategy. A strategy of culturing all children may be prohibitively expensive.

Entities:  

Keywords:  cost-benefit analysis; prevention; rheumatic heart disease

Mesh:

Substances:

Year:  2013        PMID: 23652737     DOI: 10.1161/CIRCOUTCOMES.111.000032

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  28 in total

1.  Public health: cost-effectiveness of various strategies for preventing RHD.

Authors:  Bryony M Mearns
Journal:  Nat Rev Cardiol       Date:  2013-05-28       Impact factor: 32.419

Review 2.  Acute rheumatic fever and rheumatic heart disease.

Authors:  Jonathan R Carapetis; Andrea Beaton; Madeleine W Cunningham; Luiza Guilherme; Ganesan Karthikeyan; Bongani M Mayosi; Craig Sable; Andrew Steer; Nigel Wilson; Rosemary Wyber; Liesl Zühlke
Journal:  Nat Rev Dis Primers       Date:  2016-01-14       Impact factor: 52.329

3.  Echo-based screening of rheumatic heart disease in children: a cost-effectiveness Markov model.

Authors:  Justin P Zachariah; Mihail Samnaliev
Journal:  J Med Econ       Date:  2015-02-09       Impact factor: 2.448

4.  The Cape Town Clinical Decision Rule for Streptococcal Pharyngitis in Children.

Authors:  Mark E Engel; Karen Cohen; Ronald Gounden; Andre P Kengne; Dylan Dominic Barth; Andrew C Whitelaw; Veronica Francis; Motasim Badri; Annemie Stewart; James B Dale; Bongani M Mayosi; Gary Maartens
Journal:  Pediatr Infect Dis J       Date:  2017-03       Impact factor: 2.129

5.  Low adherence to secondary prophylaxis among clients diagnosed with rheumatic fever, Jamaica.

Authors:  Sheron Boswell Thompson; Cerese Hepburn Brown; Ann Marie Edwards; Jascinth L M Lindo
Journal:  Pathog Glob Health       Date:  2014-08-11       Impact factor: 2.894

Review 6.  Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease.

Authors:  Bo Remenyi; Jonathan Carapetis; Rosemary Wyber; Kathryn Taubert; Bongani M Mayosi
Journal:  Nat Rev Cardiol       Date:  2013-04-02       Impact factor: 32.419

Review 7.  Cardiovascular disease in Africa: epidemiological profile and challenges.

Authors:  Ashley K Keates; Ana O Mocumbi; Mpiko Ntsekhe; Karen Sliwa; Simon Stewart
Journal:  Nat Rev Cardiol       Date:  2017-02-23       Impact factor: 32.419

8.  Partnership for sustainability in cardiac surgery to address critical rheumatic heart disease in sub-Saharan Africa: the experience from Rwanda.

Authors:  JaBaris D Swain; Daniel N Pugliese; Joseph Mucumbitsi; Emmanuel K Rusingiza; Nathan Ruhamya; Abel Kagame; Gapira Ganza; Patricia C Come; Suellen Breakey; Bonnie Greenwood; Jochen D Muehlschlegel; Cecilia Patton-Bolman; Agnes Binagwaho; R Morton Bolman
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

Review 9.  Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries.

Authors:  Veronika J Wirtz; Warren A Kaplan; Gene F Kwan; Richard O Laing
Journal:  Circulation       Date:  2016-05-24       Impact factor: 29.690

10.  PASCAR and WHF Cardiovascular Diseases Scorecard project.

Authors:  Mpiko Ntsekhe; Jean M Fourie; Wihan Scholtz; Oana Scarlatescu; George Nel; Karen Sliwa
Journal:  Cardiovasc J Afr       Date:  2021 Jan-Feb       Impact factor: 1.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.